Leerink Swann initiated coverage on shares of Clovis Oncology (NASDAQ:CLVS) in a research report released on Friday morning. The firm issued an outperform rating and a $100.00 price objective on the stock. Clovis Oncology, Inc. (NASDAQ:CLVS) belongs to Healthcare sector. Its weekly performance is 11.49%. On last trading day company shares ended up $48.61. Clovis Oncology, Inc. (NASDAQ:CLVS) distance from 50-day simple moving average (SMA50) is 20.42%. … Continue reading Hot News: Clovis Oncology (NASDAQ:CLVS), Nokia Corporation (ADR) (NYSE:NOK), Key Technology (NASDAQ:KTEC), The First Bancorp (NASDAQ:FNLC), Capital One Financial (NYSE:COF)